11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

October 17, 2023

Study Completion Date

December 31, 2025

Conditions
Bacterial Infections
Interventions
DRUG

11C-Trimethoprim

\[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.

Trial Locations (1)

19107

Hospital of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER